EGFR and neoplasm: Vandetanib is a tyrosine kinase inhibitor of both VEGFR-2 and EGFR, and preclinical studies have confirmed its anti-tumour effects in a range of cancer types (Wedge et al, 2002; Ciardiello et al, 2004; Taguchi et al, 2004; Williams et al, 2004; Yano et al, 2005).